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The androgens testosterone (T) and dihydrotestosterone (DHT), besides playing an important role in
prostate development and growth, are also responsible for the development and progression of benign
prostate hyperplasia (BPH) and prostate cancer. Therefore, the actions of these hormones can be
antagonized by preventing the irreversible conversion of T into DHT by inhibiting 5a-reductase (5a-R).
This has been a useful therapeutic approach for the referred diseases and can be achieved by using 5a-
reductase inhibitors (RIs). Steroidal RIs, finasteride and dutasteride, are used in clinic for BPH treatment
and were also proposed for chemoprevention of prostate cancer. Nevertheless, due to the increase in
bone and muscle loss, impotency and occurrence of high-grade prostate tumours, it is important to seek
for other potent and specific molecules with lower side effects. In the present work, we designed and
synthesized steroids with the 3-keto-D4 moiety in the A-ring, as in the 5a-R substrate T, and with car-
boxamide, carboxyester or carboxylic acid functions at the C-17b position. The inhibitory 5a-R activity, in
human prostate microsomes, as well as the anti-proliferative effects of the most potent compounds, in a
human androgen-responsive prostate cancer cell line (LNCaP cells), were investigated. Our results
showed that steroids 3, 4 and 5 are good RIs, which suggest that C-17b lipophylic amides favour 5a-R
inhibition. Moreover, these steroids induce a decrease in cell viability of stimulated LNCaP cells, in a 5a-R
dependent-manner, similarly to finasteride.
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Fig. 2. Steroidal 5a-reductase inhibitors, finasteride and dutasteride.
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The androgens testosterone (T) and dihydrotestosterone (DHT)
(Fig. 1) play an important role not only in normal prostate devel-
opment, cell proliferation and growth, but also in the genesis and
progression of benign prostate hyperplasia (BPH) and prostate
cancer [1e3]. BPH is a recurrent disease in 50% of males by the age
of 50 and 90% of males by the age of 80, being themajor responsible
for men morbidity [4], while prostate cancer is the second-leading
cause of cancer death in men [1]. T is the most abundant circulating
androgen and it is converted in prostate into DHT by the enzyme 3-
oxo-5a-steroid-4-dehydrogenase, 5a-reductase (5a-R) (Fig. 1). DHT
is the main androgen in the prostate and the major responsible for
differentiation and prostate growth [4,5].
As androgens are implicated in the development and progres-
sion of BPH and prostate cancer, the treatment of these diseases can
be achieved by antagonizing the action of these hormones by
preventing the irreversible conversion of T into DHT, through the
inhibition of 5a-R [3,4,6]. The 5a-R inhibitors (RIs) can be classified
into steroidal and non-steroidal [5]. The development of non-
steroidal RIs has increased in the last years, but they did not
show promising inhibitory activities of 5a-R when compared to
steroidal compounds. The first steroidal RIs were designed by
modifications of the T, the natural substrate of the enzyme. One of
the main modifications was the substitution of one carbon atom of
the A-, B-, C- or D-rings of the steroid framework by a heteroatom,
specially nitrogen, leading to the discovery of potent inhibitors of
human 5a-R such as 4-azasteroids, 6-azasteroids and 10-
azasteroids [7,8]. The 4-azasteroid finasteride (Fig. 2) was the first
RI to be clinically approved for the treatment of BPH in 1992 [9,10].
Ten years later, another 4-azasteroid, dutasteride (Fig. 2), was also
approved by FDA to be used for the symptomatic treatment of BPH
[6]. Finasteride and dutasteride are potent irreversible inhibitors of
5a-R forming strong ternary complexes with 5a-R-NADPH complex
[5,11]. Both RIs reduce the intraprostatic DHT levels and, therefore,
the prostatic size [3,12], being currently used in the clinic for the
treatment of BPH andwere also proposed for chemoprevention and
treatment of prostate cancer [13,14]. Despite the success of finas-
teride and dutasteride they still have some disadvantages like the
increase in bone and muscle loss, and impotency. Furthermore,
different clinical trials have demonstrated that these RIs increased
the risk of high-grade prostate cancer, which prevent FDA approval
of finasteride and dutasteride to be used for prostate cancer
treatment [5,15]. For this reason, it is important to seek for other
potent and specific molecules with lower side effects.
Previous studies highlight the importance of the 3-keto-D4-
androstan-17b-carboxamide steroids as 5a-R inhibitors [16e18]. It
has also been found that substitution at C-17b position of steroids
by lipophilic side chains, containing amide or ester groups, en-
hances 5a-R inhibitory activity by binding to a lipophilic pocket on
the enzyme [6]. In the present work, it was designed and synthe-
sized steroids with the 3-keto-D4 moiety in the A-ring, as in T, and
with carboxamide, carboxyester or carboxylic acid functions at the
C-17b position (Scheme 1). The rationale particularly focus on the
carboxamide analogues of finasteride and dutasteride (Fig. 2)Fig. 1. Biosynthesis of dihydrotestosterone from testosterone.obtained by combining in the same molecule, the A-ring of the
substrate Twith the C-17b carboxamide group of the referred RIs. In
addition, the biochemical activity of the synthesized compounds
was determined in human prostate microsomes, by a new meth-
odology recently developed by our group [19]. The anti-
proliferative effects of the most potent RIs and of finasteride were
also investigated in a human androgen-responsive prostate cancer
cell line (LNCaP cells).2. Material and methods
2.1. Chemistry
Reactions were controlled by TLC using silica gel 60 F254 plates.
Melting points (MPs) were determined on a Reichert Thermopan
hot block apparatus and were not corrected. IR spectra were
recorded on a Jasco 420 FT/IR spectrometer. The 1H NMR spectra
were recorded at 600 MHz, on a Varian Unity 600. The 13C NMR
spectra were recorded at 150 MHz on a Varian Unity 600. Chemical
shifts were referred in d values in parts permillion (ppm) downfield
from tetramethylsilane as an internal standard. All J values are
given in Hz. Mass spectra ESI were obtained with a mass spec-
trometer QIT-MS Thermo Finningan, model LCQ Advantage MAX.
Purity was determined by HPLC using a Liquid Chromatograph of
High Performance Thermo Finningan. 4-Androsten-3-one-17b-
carboxylic acid (1) was purchased from Fountain Limited (Malta).
Reagents and solvents were used as obtained from suppliers
without further purification, with exception of dichloromethane,
and pyridine, which were dried through reflux and distillation from
CaH2, being stored away from light in a brown bottle with type 4A
molecular sieves, under an atmosphere of dry N2.
All compounds possess a purity superior to 98%. The purity was
checked by HPLC with a C18-reversed phase column and water/
acetonitrile 30:70 as solvent. The purity of individual compounds
was determined from the area peaks in the chromatogram of the
sample solution.
2.1.1. 4-Androstene-17b-carboxylic acid (2)
Sodium borohydride (590.3 mg, 15.6 mmol) was added in small
portions to a cooled and stirred mixture of trifluoroacetic acid
(3.6 mL), glacial acetic acid (3.6 mL) and acetonitrile (3.6 mL). After
this, a solution of compound 1 (1.0 g, 3.16 mmol) in dry dichloro-
methane (53 mL) was added and the reaction proceeded at room
temperature, under a stream of dry nitrogen, until all the starting
material had been consumed (3 h 20 min by TLC). The reaction
mixture was neutralized with 10% NaHCO3, extracted with chloro-
form (4  100 mL) and the organic layer washed with water
(4  100 mL), dried over anhydrous Na2SO4, filtered and concen-
trated todryness. Crystallization fromethyl acetate/hexane afforded
the pure compound 2 (680.5 mg, 71%) as white crystals. Mp(ethyl ac-
etate/hexane): 205e208 C; IR (NaCl plates, CHCl3): ymax ¼ 3399 (OeH
carboxylic acid), 3020 (HeC]), 1701 (C]O carboxylic acid), 1676
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Scheme 1. Synthesis of 5a-reductase inhibitors from 4-androsten-3-one-17b-carboxylic acid. Reagents and conditions: (i) CF3COOH, CH3COOH, CH3CN, NaBH4, dry dichloromethane,
RT, 3 h 30 min; (ii) N,N-dimethylformamide, triethylamine, tert-butylamine or n-propylamine or n-hexylamine or 2,5-bis-(trifluoromethyl)aniline, BOP, dichloromethane, RT; (iii)
1st: SOCl2, dry tetrahydrofuran, dry pyridine, RT, 40 min; 2nd: 2,5-bis-(trifluoromethyl)aniline, dry tetrahydrofuran, dry pyridine, 66 C, 5 h.
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d¼ 0.75 (3H, s, 18-H3), 1.02 (3H, s, 19-H3), 2.38 (1H, dd, J17a,16a¼ 9.4,
J17a,16b ¼ 9.4, 17a-H), 5.30 (1H, bs, 4-H), 10.46 (1H, bs, COOH); 13C
NMR (150 MHz, CDCl3): d ¼ 13.3 (C-18), 19.2 (C-19), 19.4, 21.2, 23.4,
24.5, 25.7, 32.5, 33.2, 36.1, 37.1, 37.8, 38.2, 44.3, 54.4, 55.1, 55.9, 119.3
(C-4), 144.7 (C-5), 179.9 (C20]O); ESIm/z 303.4 ([M þ H]þ, 100%).
2.1.2. General method for obtaining N-tert-butyl-3-oxoandrost-4-
ene-17b-carboxamide (3), N-propyl-3-oxoandrost-4-ene-17b-
carboxamide (4), N-hexyl-3-oxoandrost-4-ene-17b-carboxamide
(5) 1H-benzo[d][1,2,3]triazol-1-yl 3-oxoandrost-4-ene-17b-
carboxylate (7)
Compound 1 was dissolved in N,N-dimethylformamide and
triethylamine. The solutionwas cooled in an ice-water bath and the
amine was added followed by a solution of (benzotriazol-1-yloxy)
tris(dimethylamino)phosphonium hexafluorophos-phate (BOP) in
dichloromethane. The reaction mixture was stirred at 0 C for
30 min and then at room temperature for 1 h 20 min to 3 h.
Dichloromethane was removed under reduced pressure and the
resulting solution diluted with water (25 mL) and extracted with
ethyl acetate (2  25 mL). The organic layer was washed succes-
sively with HCl 1 N (3  25 mL), water (25 mL), NaHCO3 1 M
(3  25 mL) and water (2  25 mL), dried over anhydrous MgSO4,
filtered and concentrated to dryness. The residue obtained was
purified by silica gel column chromatography with petroleum ether
40e60 C/ethyl acetate gradient, except for compound 7, giving the
pure compounds.
2.1.2.1. N-tert-Butyl-3-oxoandrost-4-ene-17b-carboxamide (3).
Compound 1 (200.0 mg, 0.632 mmol); N,N-dimethylformamide
(1.3 mL); triethylamine (0.1 mL, 0.72 mmol); tert-butylamine
(0.1 mL, 0.95 mmol); BOP (279.1 mg, 0.63 mmol); dichloromethane
(1.6 mL); reaction time: 3 h; yield (162.0 mg, 69%) as white solid.
Mp(petroleum ether 40e60 C/ethyl acetate): 219e221 C [Lit. 218e219 C
from acetone] [20]; IR (ATR): ymax ¼ 3366 (NeH), 1661 (C]O
amide and C]O ketone), 1615 (C]C) cm1; 1H NMR (CDCl3,
600 MHz): d ¼ 0.72 (3H, s, 18-H3), 1.18 (3H, s, 19-H3), 1.35 (9H, s, 3eCH3), 5.08 (1H, s, eNH), 5.73 (1H, s, 4-H); 13C NMR (150 MHz,
CDCl3): d ¼ 13.1 (C-18), 17.4 (C-19), 21.0, 23.2, 24.4, 29.0 (3 CH3),
31.9, 32.8, 34.0, 35.6, 35.7, 38.5, 38.6, 43.5, 51.1, 53.8, 55.6, 57.5,
123.9 (C-4), 171.1 (C-5), 171.6 (C20]O), 199.5 (C3]O); ESI m/z 372.6
([M þ H]þ, 100%).
2.1.2.2. N-Propyl-3-oxoandrost-4-ene-17b-carboxamide (4).
Compound 1 (200.0 mg, 0.632 mmol); N,N-dimethylformamide
(1.3 mL); triethylamine (0.1 mL, 0.72 mmol); propylamine (0.1 mL,
0.95 mmol); BOP (279.1 mg, 0.63 mmol); dichloromethane
(1.6 mL); reaction time: 1 h 20 min; yield (122.6 mg, 54%).
Mp(petroleum ether 40e60 C/ethyl acetate): 147e149 C; IR (NaCl plates,
CHCl3): ymax ¼ 3368 (NeH), 1656 (C]O amide and C]O ketone),
1617 (C]C) cm1; 1H NMR (CDCl3, 600 MHz): d ¼ 0.72 (3H, s, 18-
H3), 0.92 (3H, t, J ¼ 7.4 Hz, eCH3), 1.18 (3H, s, 19-H3), 2.40 (1H, dd,
J17a,16a ¼ 14.6, J17a,16b ¼ 4.9, 17a-H), 3.12e3.33 (2H, m, eCH2e),
5.38 (1H, bs, eNH), 5.72 (1H, s, 4-H); 13C NMR (150 MHz, CDCl3):
d ¼ 11.4 (C-18), 13.2 (eCH3), 17.3 (C-19), 20.9, 23.1, 23.6, 24.4, 31.9,
32.8, 33.9, 35.6, 35.7, 38.6, 41.2, 43.6, 53.8, 55.5, 57.0, 123.8 (C-4),
171.1 (C-5), 172.4 (C20]O), 199.5 (C3]O); ESI m/z 358.8
([M þ H]þ, 100%).
2.1.2.3. N-Hexyl-3-oxoandrost-4-ene-17b-carboxamide (5).
Compound 1 (177.8 mg, 0.562 mmol); N,N-dimethylformamide
(1.3 mL); triethylamine (0.09 mL, 0.64mmol); hexylamine (0.11mL,
0.84 mmol); BOP (167.2 mg, 0.38 mmol); dichloromethane
(1.6 mL); reaction time 3 h; yield (78.4 mg, 35%). Mp(petroleum ether
40e60 C/ethyl acetate): 56e61 C; IR (NaCl plates, CHCl3): ymax ¼ 3389
(NeH), 1656 (C]O amide and C]O ketone), 1621 (C]C) cm1; 1H
NMR (CDCl3, 600 MHz): d ¼ 0.72 (3H, s, 18-H3), 0.87 (3H, t,
J ¼ 7.0 Hz, eCH3), 1.18 (3H, s, 19-H3), 2.40 (1H, dd, J17a,16a ¼ 14.5,
J17a,16b¼ 5.0, 17a-H), 3.15e3.35 (2H, m,eCH2e), 5.34 (1H, bs, eNH),
5.72 (1H, s, 4-H); 13C NMR (150MHz, CDCl3): d¼ 13.2 (C-18),13.9 (e
CH3), 17.4 (C-19), 20.9, 22.5, 23.6, 24.4, 26.6, 29.8, 31.4, 31.9, 32.8,
33.9, 35.6, 35.7, 38.3, 38.6, 39.5, 43.6, 53.8, 55.5, 57.0, 123.9 (C-4),
171.1 (C-5), 172.3 (C20]O), 199.4 (C3]O); ESI m/z 400.6 ([M þ H]þ,
100%).
C. Amaral et al. / Biochimie 95 (2013) 2097e210621002.1.2.4. 1H-Benzo[d][1,2,3]triazol-1-yl 3-oxoandrost-4-ene-17b-
carboxylate (7). Compound 1 (200.1 mg, 0.632 mmol); N,N-dime-
thylformamide (1.3 mL); triethylamine (0.1 mL, 0.72 mmol); 2,5-
bis(trifluoromethyl)aniline (0.15 mL, 0.95 mmol); BOP (279.8 mg,
0.63 mmol); dichloromethane (3 mL); reaction time: 5 h, without
completion. Crystallization from ethyl acetate gave the pure com-
pound 7 (200.5 mg, 73%) as white needles. Mp(ethyl acetate): 210e
213 C; IR (NaCl plates, chloroform solution): ymax ¼ 3311 (HeC]
aromatic), 3021 (HeC]), 1809 (C]O ester), 1669 (C]C), 1616 and
1447 (C]C arom), 1070 (CeO ester) cm1; 1H NMR (CDCl3,
600 MHz): d ¼ 0.98 (3H, s, 18-H3), 1.22 (3H, s, 19-H3), 2.86 (1H, dd,
J17a,16a¼9.4Hz, J17a,16b¼9.4Hz,17a-H), 5.75 (1H, s, 4-H), 7.41 (1H,m,
J¼ 7.4, J¼ 0.9, J¼ 0.9, 30-H or 60-H), 7.42 (1H,m, J¼ 7.9, J¼ 7.1, J¼ 0.8,
40-H or 50-H), 7.54 (1H, m, J ¼ 7.9, J ¼ 7.1, J ¼ 0.8, 40-H or 50-H), 8.06
(1H, m, J ¼ 7.4, J ¼ 0.9, J ¼ 0.9, 30-H or 60-H); 13C NMR (150 MHz,
CDCl3): d ¼ 13.8 (C-18), 17.4 (C-19), 20.9, 24.0, 24.5, 31.8, 32.7, 33.9,
35.70, 35.74, 37.9, 38.6, 45.2, 52.7, 53.5, 55.5,108.2 (C-4),120.5,124.0,
124.7,128.5,128.6,143.5,170.1 (C-5),170.4 (C20]O),199.3 (C3]O); EI
m/z 434.0 ([M þ H]þ, 4%); ESIm/z 434.5 ([M þ H]þ, 100%).
2.1.2.5. 17b-N-[2,5-bis(Trifluoromethyl)phenyl] 3-oxoandrost-4-ene-
17b-carboxamide (6). A solution of compound 1 (400.0 mg,
1.26 mmol) in dry tetrahydrofuran (15 mL) and dry pyridine
(0.1 mL), under dry nitrogen, was cooled at 2 C. To this solution,
thionyl chloride (0.12 mL, 1.64 mmol) was added and the reaction
mixture was stirred at 2 C for 20 min and then at room tem-
perature for 40 min. The reaction mixture was filtered and the
obtained residue washed with toluene. The filtered was concen-
trated under vacuum giving a yellow oil which was diluted with
dry tetrahydrofuran (20 mL) and dry pyridine (0.1 mL). To the
resulting solution it was added 2,5-bis-(trifluoromethyl)aniline
(0.22 mL, 1.39 mmol) and the reaction mixture was refluxed for
5 h. After that, it was diluted with chloroform (300 mL), and the
resulting organic layer was washed with HCl 1 N (4  100 mL),
brine (4  100 mL) and water (100 mL), dried over anhydrous
Na2SO4, filtered and concentrated. The residue obtained was pu-
rified by silica gel column chromatography with hexane/ethyl ac-
etate gradient giving the pure compound 6 (230.9 mg, 35%) as a
white solid. Mp(hexane/ethyl acetate): 203e207 C; IR (NaCl plates,
CHCl3): ymax ¼ 3315 (HeC] aromatic), 3017 (HeC]), 1706 (C]O
ketone), 1664 (C]O amide), 1645 (C]C), 1616 and 1473 (C]C
aromatic), 1137 (CeF), 1591 (NeH) cm1; 1H NMR (CDCl3,
600 MHz): d ¼ 0.82 (3H, s, 18-H3), 1.19 (3H, s, 19-H3), 5.74 (1H, s, 4-
H), 7.44 (1H, d, J40 ,30 ¼ 8.2, 40-H), 7.50 (1H, s, 60-H), 7.72 (1H, d,
J30 ,40 ¼ 8.2, 30-H), 8.78 (1H, s, eNH); 13C NMR (150 MHz, CDCl3):
d ¼ 13.2 (C-18), 17.4 (C-19), 20.9, 23.6, 24.3, 31.9, 32.7, 33.9, 35.6,
35.7, 37.9, 38.6, 44.5, 53.6, 55.7, 58.4, 120.2 (C-40), 120.4 (C-60),
124.0 (C-4), 126.7 (C-30), 170.7 (C-5), 171.4 (C20]O), 199.4 (C3]O);
ESI m/z 528.5 ([M þ H]þ, 100%).
2.2. Biochemistry
2.2.1. Stock solutions
The individual stock internal standard solutions of testosterone-
d3 (T-d3; 98 atom% D) (Fluka, Neu-Ulm, Germany) at 3.47 mM and
dihydrotestosterone 13C3 (DHT-13C3, 99 atom% 13C) (SigmaeAldrich,
Chemie GmbH, Steinheim, Germany) at 3.44 mM were prepared in
MeCN (Fluka). The stock solution of each steroid was prepared in
100% DMSO (SigmaeAldrich). The stock solution of testosterone (T,
99% purity grade) (Fluka) and dihydrotestosterone (DHT, 99% purity
grade) (SigmaeAldrich) was prepared in MeOH for gas chroma-
tographyemass spectrometry (GCeMS) analysis (Fluka) or pre-
pared in absolute ethanol (Fluka) for cell culture. All these solutions
were stored at 20 C before use. Appropriate dilutions were
freshly prepared just prior the assays and the final concentration ofDMSO and ethanol in culture medium was less than 0.05% and
0.01%, respectively.
2.2.2. Preparation of prostate microsomes
Human prostate microsomes were prepared as previously
described [19] and according to [21e23], with some modifications.
Human prostate tissues, from BPH patients, provided by a local
hospital after patient informed consent,were collected after surgery
andplaced in cold20mMsodiumphosphate buffer (pH6.5),washed
and stored at 80 C before use. Briefly, to prepare prostate micro-
somes, the prostatic tissues were weighed and homogenized in a
Polytron homogenizer with a solution of 20 mM sodium phosphate
buffer (pH 6.5) containing 0.32M sucrose and 0.1mMdithiothreitol
(DTT; 1:1, w/v) (SigmaeAldrich). The homogenate was centrifuged
at 5000 g for 30min. The supernatant obtainedwas centrifuged at
20,000 g for 30min and then at 54,000 g for 45min to obtain the
microsomal pellet, that was washed and resuspended in 20 mM
sodium phosphate buffer (pH 6.5) containing 0.32 M sucrose,
0.1 mM DTT and glycerol and stored at 80 C. The protein content
was determined by the Bio-Rad protein assay (Bio-Rad, Laboratories
Melville, NY, USA) using bovine serum albumin (BSA) (Sigmae
Aldrich) as standard. All the procedures were carried out at 4 C.
2.2.3. 5a-reductase assay
In order to determine the anti-5a-reductase activity of the ste-
roids in human prostatic microsomes, it was used a method based
on a dispersive liquideliquid microextraction (DLLME) procedure,
followed by the GCeMS method previously described [19].
The synthesized steroids were dissolved in DMSO and diluted in
40 mM sodium phosphate buffer (pH 6.5).
As a screening assay, to determine the percentage of reductase
inhibitionofeachcompound, itwasused50mgofprostatemicrosomal
protein, 500 nM of T, 1 mM of DTT, 25 mL of DMSO and 1 mM of each
steroidal compound in40mMof sodiumphosphate buffer (pH6.5), in
a final reaction volume of 0.5 mL. To determine the IC50 value of the
steroids that presented an anti-reductase activity higher than 60%, it
was used different concentrations of each inhibitor (0.01e2 mM). The
enzymatic reactionwas initiated by the addition of 250 mMof reduced
nicotinamide adenine dinucleotide phosphate (NADPH) (Sigmae
Aldrich) and incubations were performed in a shaking water bath at
37 C for60min.The reductasereactionswerestoppedbytheaddition
of500mLofMeCN in ice and the steroids, TandDHT,were extractedby
DLLME. Then, to this enzymatic mixture it was added 50 mL of Td3
(175 nM) and DHT-13C3 (175 nM) and 50 mL of the high purity
extractive solvent trichloroethylene (C2HCl3) (Fluka). This mixture
was transferred to a conical tube with 3 mL of H2O, the tubes were
hand-shaken and centrifuged at 5000  g for 3 min. After centrifu-
gation, the lower phase (30 mL) that contained the extracted steroids
was transferred to a newvial anddried using a gentle nitrogen stream
at room temperature. After evaporation, the steroidswere silylated by
addition of 30 mL of a solution containingN-methyl-N-(trimethylsilyl)
trifluoroacetamide (MSTFA, 98.5% purity grade) (Fluka), ammonium
iodide (NH4I, 99% purity grade) and 1,4-dithioerythritol (DTE, 99%
puritygrade) (SigmaeAldrich) (MSTFAþNH4IþDTE) during 5min in
a household microwave (600W), and 1 mL of the extract was injected
in the GCeMS system. The GCeMS conditions are according our
previously reportedmethod [19].All theexperimentswereperformed
in triplicate. As a reference control it was used the RI finasteride at
1 mM (Sequoia Research Products Ltd, Pangbourne, UK).
2.3. Anti-proliferative effects
2.3.1. Cell culture
The androgen-sensitive human prostate adenocarcinoma cells,
LNCaP, were purchased from the American Type Culture Collection
C. Amaral et al. / Biochimie 95 (2013) 2097e2106 2101(ATCC, Manassas, VA, USA) and maintained in RPMI 1640 medium
(ATCC modification) with 4.5 g/L D-glucose, 2.383 g/L HEPES buffer,
300 mg/L L-glutamine, 1.5 g/L sodium bicarbonate, 110 mg/L of so-
dium pyruvate, 1% penicillinestreptomycineamphotericin B and
10% of heat-inactivated fetal bovine serum (FBS) (Gibco Invitrogen
Co., Paisley, Scotland, UK). The LNCaP cells were regularly grown at
37 C in 5% CO2 atmosphere and mediumwas changed every three
days. For LNCaP assays, cells were used between the passages 5 and
20, since beyond 25 passages reduced androgen responsiveness
was already observed [24,25].
The biological effects of the steroidal compounds that presented
an anti-reductase activity higher than 60% were evaluated in LNCaP
cells. Before the addition of compounds, cells were cultured during
3 days in a steroid-free RPMImediumwith L-glutamine but without
phenol red (Gibco Invitrogen Co), containing 1 mmol/L of sodium
pyruvate, 1% of penicillinestreptomycineamphotericin B and 5% of
pre-treated charcoal heat-inactivated fetal bovine serum (CFBS), in
order to avoid the interference of the steroids present in FBS and of
the oestrogenic effects of phenol-red [26]. After that time, steroids
in study were added with or without the proliferation inducing
agent (T or DHT). All the experiments were performed according to
these conditions and themedium and drugs were refreshed every 3
days.
2.3.2. Cell viability
To evaluate the effects of each steroidal compound in LNCaP
cells viability, the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-
2,5-difenyltetrazolium (MTT) (SigmaeAldrich, Saint Louis, USA)
and lactate dehydrogenase (LDH) release (Promega Corporation,
Madison, USA) assays were performed. After confluency, LNCaP
cells were cultured in 96-well plates at a cellular density of
3  104 cells/mL (for 2, 3 and 4 days) and 1.5  104 cells/mL (for 6
days) and after 3 days of steroid-free culture the cells were treated
with different concentrations of each compound (1e50 mM)
without any proliferation inducing agent, or with 10 nM of T, or
with 10 nM of DHT during 2, 3, 4 and 6 days. Cells incubated with
10 nM of the proliferation inducing agent plus 0.05% of DMSO
were used as control. Finasteride was used as a reference RI.
After each incubation time, MTT (0.5 mg/mL) was added to each
well and cells were incubated for 2 h and 30 min at 37 C in 5% CO2.
The formazanwas quantified spectrophotometrically by addition of
DMSO:isopropanol mixture (3:1). The LDH release was measured
by using CytoTox 96 nonradioactive cytotoxicity assay kit, according
to the manufacturer’s protocol. The results are expressed as a per-
centage of the untreated control cells. All the assays were per-
formed in triplicate in three independent experiments.
2.4. Statistical analysis
Statistical analysis of data was performed using analysis of
variance (ANOVA) followed by Bonferroni test for multiple com-
parisons and values of p < 0.05 were considered as statistically
significant. The data are expressed as the mean  SEM.
3. Results
3.1. Chemistry
The synthesis of compound 2 (Scheme 1), the C-3 deoxygenated
derivative of 4-androsten-3-one-17b-carboxylic acid 1, was per-
formed by submitting 1 to a reduction with sodium borohydride in
trifluoroacetic acid, glacial acetic acid, and acetonitrile giving
compound 2, in 71% yield [27].
The amides 3, 4 and 5 (Scheme 1) were obtained in 69%, 54% and
35% yield, respectively, by reacting acid 1 with tert-butylamine, n-propylamine or n-hexylamine, in dimethylformamide and
dichloromethane, using triethylamine and the coupling agent BOP
[28] probably through the intermediate 7. In spite of amide 3 has
already been prepared in 89% [20] and in 95% [29] using thionyl
chloride followed by tert-butylamine, in this work we present a
one-step reaction using milder conditions.
An attempt to prepare amide 6 from 1 (Scheme 1) using the
abovementioned conditions with the amine 2,5-bis-(tri-
fluoromethyl)aniline, afforded 7 in 73% yield. In this case, the
activated intermediate ester 7 was unable to react with the amine
2,5-bis-(trifluoromethyl)aniline to give 6, probably due to the weak
nucleophilicity of the deactivated aromatic amine 2,5-bis-(tri-
fluoromethyl)aniline. Consequently, the final product was only
compound 7. In order to overcome this limitation, amide 6 was
obtained by a two-step reaction sequence [30]. In the first step, the
C-17 carboxylic acid 1 was activated to the respective acyl chloride
by treatment with thionyl chloride, in dry tetrahydrofuran and in
the presence of dry pyridine. In the second step, the acyl chloride
was subjected to reaction with 2,5-bis-(trifluoromethyl)aniline in
dry tetrahydrofuran and in the presence of dry pyridine providing
compound 6 in 35% yield.
3.2. 5a-Reductase activity
To evaluate the anti-5a-reductase activity of each steroidal
compound in human prostatic microsomes, it was applied a
DLLME-GCeMS method previously developed by our group, that
identifies and quantifies T and DHT, using the internal standards
Td3 and DHT-13C3 [19]. The ratio between T/Td3 and DHT/DHT-13C3
allowed the quantification of T and DHT produced after 5a-reduc-
tase reaction estimating the anti-5a-reductase activity of each
compound.
Firstly, it was evaluated the percentage of 5a-reductase inhibi-
tion (%) of the synthesized RIs at 1 mM (Table 1 and Fig. 3A). As a
reference compound it was used the RI finasteride, that presented
an 84.62  1.21% of 5a-reductase inhibition, which is in accordance
to what has been already described (80%e90%) in human prostate
microsomes [31]. Three of the studied steroids, 3, 4 and 5, pre-
sented an anti-reductase activity higher than 60%, 73.08  3.05%,
69.33  1.03% and 63.56  1.08%, respectively. For these steroids,
the IC50 was also determined (0.37 mM, 0.46 mM and 0.61 mM,
respectively) (Table 1 and Fig. 3B). Our results demonstrated that
steroid 3 is the most potent RI in human prostate microsomes.
3.3. Effects of steroids in LNCaP cells viability
The effects of the most potent RIs 3, 4, 5 and finasteride (1e
50 mM) in LNCaP cells viability were investigated using MTT and
LDH release assays after 2, 3, 4 and 6 days of treatment.
To evaluate the adequate concentrations of the inducing pro-
liferation agents, LNCaP cells were cultured with different con-
centrations of T or DHT (0.1e100 nM). In our experimental
conditions, the concentration of 10 nM for T and DHT was selected
as the most adequate to induce proliferation of LNCaP cells in vitro
(data not shown).
It was evaluated the biological effect of RIs 3, 4, 5 and finasteride
(1e50 mM) on LNCaP T-treated cells and, as observed in Fig. 4, RIs
induced a decrease in cell viability in a dose- and time-dependent
manner. Compound 5 and finasteride caused a significant (p< 0.05;
p < 0.01; p < 0.001) decrease in cell viability for all the concen-
trations and all days of treatment, except for the lowest concen-
tration (1 mM) after 2 days. Compounds 3 and 4 presented a
significant (p < 0.05; p < 0.01; p < 0.001) reduction in cell viability
for the higher concentrations (10e50 mM) and all times of incu-
bation, except after 2 (1 and 5 mM) and 3 (1 mM) days of treatment
Table 1
The anti-5a-reductase activity of synthetized steroids in human prostate
microsomes.
Compounds Reductase inhibition (%)  SEM IC50 (mM)
1 29.55  3.09 e
2 11.04  3.42 e
3 73.08  3.05 0.37
4 69.33  1.03 0.46
5 63.56  1.08 0.61
6 22.44  2.03 e
7 49.20  2.51 e
Finasteride 84.62  1.21 0.096 [19]
C. Amaral et al. / Biochimie 95 (2013) 2097e21062102for the lower concentrations. As shown in Fig. 4E and F, steroid 3 is
the most efficient and finasteride the less potent in decreasing cell
viability. Cells treated with T were considered as control.
It was also evaluated the LDH release in T-treated LNCaP cells
after 3 days of treatment with compounds. As finasteride, steroids 3
and 5, for the higher concentration (50 mM), induced a significant
(p < 0.05; p < 0.01) release of LDH (Fig. 5), therefore the effects of
these compounds were further studied between 1 and 25 mM. In
addition, to confirm if compounds caused by themselves any effect
in LNCaP cell growth, RIs treated-cells were cultured in the absence
of T or DHT for 3 days. As it can be observed in Fig. 6, all the studied
steroids showed a minimal growth-inhibitory activity. Only for the
higher concentration (25 mM), steroids 3 and 5 presented a signif-
icant (p < 0.05) reduction in cell viability.
The ability of compounds to inhibit the growth of DHT-
stimulated LNCaP cells was also evaluated after 3 and 6 days. Our
results demonstrate that RIs present a significant (p < 0.05;
p < 0.01; p < 0.001) inhibitory growth of DHT-treated cells (Fig. 7).
Though, to understand if these effects are dependent on reductase
inhibition, it was compared their effects on T versus DHT-treated
cells. By the analysis of Fig. 7A and B, it is observed that finaste-
ride and steroid 3 induced significant differences (p < 0.05;
p < 0.01) for the higher concentrations (10 and 25 mM) in cell
viability, after 3 days and for all the concentrations after 6 days.
Steroid 4 caused significant differences (p < 0.05; p < 0.01;
p < 0.001) for all the concentrations and all days of treatment,
except for 1 mM after 3 days (Fig. 7C). Finally, for steroid 5 it was
only observed significant differences (p < 0.05; p < 0.01) for the
higher concentrations (10 and 25 mM) after 6 days (Fig. 7D), which
suggests that the effects of this steroid on DHT-treated cells is only
time-dependent.A B
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Fig. 3. The anti-5a-reductase activity of the synthesized steroids in human prostate micr
obtained by three independent experiments carried out in triplicate. Finasteride (F) was us4. Discussion
In this study it was investigated the inhibitory activity of 5a-R of
a set of synthesized steroids. It is known that one of the key
structural requirements for 5a-R inhibition is the presence of a 4-
en-3-one function in the A-ring and a lipophilic 17b-side chain in
the D-ring of steroids [6]. Furthermore, it has been found that the
presence at C-17b of lipophilic amides or esters enhances potency
by binding to a lipophilic pocket on the enzyme [6]. In this study,
these features were investigated by studying different C-17b
chemical modifications (amide, ester or carboxylic acid functions)
in the potential steroidal RIs.
The evaluation of anti-5a-R activity of each steroid in human
prostatic microsomes was performed by a DLLME-GCeMS previ-
ously developed method [19]. Based on the results displayed in
Table 1, it is possible to infer that C-17b carboxylic acid analogues (1
and 2) of T are weak inhibitors of 5a-R, particularly the 3-deoxo
analogue 2. In fact, several descriptions referred the importance
of a sp2-hybridized center at C-3 and C-4 positions of steroids for
the 5a-R inhibitory activity [6]. Therefore, the lack of that center at
C-3 as in 2, results in a decrease in the activity (11.04  3.42% in-
hibition). Concerning analogue 1, it was already reported as a
competitive inhibitor of 5a-R, with 87.7% inhibition for the micro-
somal enzyme of human skin [6,32]. However, in our experimental
conditions, using the prostate microsomal enzyme, analogue 1
showed only 29.55  3.09% inhibition.
Among the amides synthesized and evaluated, the N-tert-
butylcarboxamide 3 (Scheme 1) showed the best inhibitory activity,
with an IC50 of 0.37 mM (Table 1). In this case, we combined in the
same molecule, the A-ring of the substrate T and the C-17b car-
boxamide of finasteride (Fig. 2), which resulted in a potent inhibitor.
Regarding the N-propylcarboxamide 4 and the N-hexylcarbox-
amide 5 (Scheme 1) it is possible to infer that these steroids are also
strong inhibitors (IC50 of 0.46 and 0.61 mM, respectively) (Table 1).
Further, the N-propylcarboxamide 4 is slightly more active than the
N-hexylcarboxamide 5, however both of them are less active than
N-tert-butylcarboxamide 3, showing that a hindered N-alkyl group,
as in 3, or a shorter N-alkyl linear chain, as in 4, in the C-17b car-
boxamide function favours the 5a-R inhibitory activity.
Concerning compound 6, in spite of having in the C-17b position
the same group as dutasteride, the N-[2,5-bis(trifluoromethyl)
phenyl]carboxamide, surprisingly it only exhibits minimal inhibitory
activity (22.44 2.03%). This result reveals that alongwith the C-17b
carboxamide group, the steroidal A-ring type also determines the0
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Fig. 4. Effects of finasteride (F), (A), steroid 3 (B), steroid 4 (C) and steroid 5 (D) in cell viability of T-treated LNCaP cells, evaluated by MTT assay. Comparison of the effects of all the
RIs, after 3 (E) and 6 (F) days of treatment. LNCaP cells were cultured with different concentrations of each RI (1e50 mM) and T at 10 nM during 2, 3, 4 and 6 days. Cells cultured with
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it is a moderate inhibitor (49.20  2.51% inhibition).
In this study it was also evaluated the effect of the most potent
RIs, steroids 3, 4, 5 and finasteride in LNCaP cells viability. This cellMμ1
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Fig. 5. Effects of RIs finasteride (F) 3, 4 and 5 on membrane integrity of LNCaP cells, by
LDH release assay. LNCaP cells were cultured with different concentrations of each RI
(1e50 mM) and 10 nM of T during 3 days. Cells cultured with T represent the maximum
of cell viability and were considered as control. Results are the mean  SEM of three
independent experiments, performed in triplicate. Significant differences between the
control and cells with finasteride, F, are denoted by dd (p < 0.01), with 3 by f (p < 0.05)
and with 5 by l (p < 0.05). Finasteride (F) was used as reference RI.line is a human androgen-responsive prostate cancer cell line, that
is a good model to study hormonal therapies for this disease
[33]. LNCaP cells are a biological model similar to a non-invasive
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stimulation induced by oestrogens or androgens in vitro and in vivo
[35,36]. Therefore, the effects of the most potent steroids were
studied in LNCaP cells treated with 10 nM of T or DHT.
The results obtained with T-treated LNCaP cells with RIs 3, 4, 5
and finasteride after 2, 3, 4 and 6 days indicate that compoundsinduced a significant decrease in cell viability, being steroid 3 the
most potent, even more than finasteride. Other studies also
demonstrated that finasteride (1 and 5 mM) inhibited growth of
LNCaP cells treated with T, though only after 9 days of treatment
[37e39]. Golbano J. M. et al. (2008) demonstrated that finasteride
significantly induced a reduction in LNCaP cell viability in a dose-
C. Amaral et al. / Biochimie 95 (2013) 2097e2106 2105and time-dependent manner due to apoptosis via Bcl-2 family and
caspase activity [33].
To investigate if the biological effects induced by all the RIs were
due to 5a-R inhibition, it was compared their effects in T- versus
DHT-treated cells. It was observed significant differences for all
steroids, being the effects on T-treated cells more remarkable than
on DHT-treated cells. For steroid 5 this effect was only noticeable
with the extension of treatment. These results suggest that these
steroids induced the reduction in cell viability in a 5a-R-dependent
manner, by inhibiting 5a-reductase and the conversion of T into
DHT. Nevertheless, it cannot be discarded the hypothesis that other
mechanisms may also be involved, since in the presence of DHT,
these RIs also induced a slight decrease in LNCaP cell viability,
especially with the extension of treatment. Other studies had
already demonstrated that finasteride reduce cell growth of DHT-
treated LNCaP cells in a dose-dependent manner [37e41].
In order to understand if the ability of steroids to decrease
viability of T- and DHT-treated cells was not dependent on their
intrinsic toxicity, it was also evaluated their effects in cells without
a stimulatory effect. Our data showed that all the steroids induced a
minimal growth-inhibitory activity in cells, on their own. This
observation was already reported for finasteride in other studies
[33,37e40].
5. Conclusion
Taking into account the studied compounds, it is possible to
conclude that the C-17b lipophilic carboxamides along with the 3-
keto-D4 moiety in the A-ring seem to be essential key features for
achieving 5a-reductase inhibitory activity, being the steroid with a
C-17 N-tert-butlycarboxamide group (3), the best RI. Furthermore,
steroids 3, 4 and 5 as well as finasteride induced a decrease in
viability of stimulated LNCaP cells in a 5a-R dependent-manner,
being the synthesized steroids 3, 4, and 5 even more effective
than finasteride. Our results also suggest that other mechanisms
are involved in diminishing cell viability. This study can help in the
future design of new steroidal RIs contributing to the discovery of
new drugs with fewer side effects.
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